SAN FRANCISCO, April 25 - Accelrys will functionally annotate 10,000 protein sequences for Incyte, the companies announced Thursday.
The deal calls for Accelrys to use its GeneAtlas application to annotate selected sequences from Incyte's collection of rarely expressed human genes. The 3D annotations will be delivered to Incyte along with Accelrys' Discovery Studio data mining software to enable viewing the annotations and structural models, the companies said.
Financial details of the agreement were not disclosed.
"Incyte has an appreciable number of proprietary gene sequences for which little is known about the possible functions of their encoded protein," Robert Stein, Incyte's president and chief scientific officer, said in a statement. "Accelrys' high throughput technologies for predicting protein structure and recognizing similarities to other proteins of known function should be very useful in gaining a functional perspective on many of Incyte's proprietary gene sequences."
Accelrys is a wholly-owned subsidiary of Pharmacopeia.